- Home
- SLP vs BWAY Comparison
SLP vs BWAY Comparison
Compare SLP & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLP
- BWAY
- Stock Information
- Founded
- SLP 1996
- BWAY 2003
- Country
- SLP United States
- BWAY Israel
- Employees
- SLP N/A
- BWAY N/A
- Industry
- SLP EDP Services
- BWAY Medical/Dental Instruments
- Sector
- SLP Technology
- BWAY Health Care
- Exchange
- SLP Nasdaq
- BWAY Nasdaq
- Market Cap
- SLP 282.4M
- BWAY 280.7M
- IPO Year
- SLP 1997
- BWAY 2019
- Fundamental
- Price
- SLP $15.43
- BWAY $16.06
- Analyst Decision
- SLP Buy
- BWAY Strong Buy
- Analyst Count
- SLP 7
- BWAY 2
- Target Price
- SLP $29.50
- BWAY $18.00
- AVG Volume (30 Days)
- SLP 445.5K
- BWAY 77.7K
- Earning Date
- SLP 10-22-2025
- BWAY 11-11-2025
- Dividend Yield
- SLP N/A
- BWAY N/A
- EPS Growth
- SLP N/A
- BWAY 515.14
- EPS
- SLP N/A
- BWAY 0.11
- Revenue
- SLP $80,383,000.00
- BWAY $46,084,000.00
- Revenue This Year
- SLP $12.75
- BWAY $339.49
- Revenue Next Year
- SLP $3.06
- BWAY $21.74
- P/E Ratio
- SLP N/A
- BWAY $58.19
- Revenue Growth
- SLP 20.01
- BWAY 26.50
- 52 Week Low
- SLP $12.39
- BWAY $7.84
- 52 Week High
- SLP $37.67
- BWAY $17.00
- Technical
- Relative Strength Index (RSI)
- SLP 60.71
- BWAY 60.10
- Support Level
- SLP $13.78
- BWAY $15.01
- Resistance Level
- SLP $14.46
- BWAY $17.00
- Average True Range (ATR)
- SLP 0.62
- BWAY 0.66
- MACD
- SLP 0.19
- BWAY -0.07
- Stochastic Oscillator
- SLP 71.91
- BWAY 60.50
About SLP Simulations Plus Inc.
Simulations Plus Inc is engaged in the software industry. It includes two segments. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.
About BWAY BrainsWay Ltd.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.